26
Participants
Start Date
February 15, 2017
Primary Completion Date
March 30, 2021
Study Completion Date
March 30, 2021
Parsaclisib
Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
Hexal
Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.
Gazyvaro
Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
Semmelweis Egyetem, Budapest
Clinical Research Alliance, Lake Success
Center for Cancer and Blood Disorders (CCBD) - Bethesda, Bethesda
A.O. Spedali Civili, Brescia
UO Ematologia ASST Spedali Civili, Brescia
Hospital Universitario Gregorio Marañón, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario La Paz, Madrid
Centro di Riferimento Oncologico, Aviano
Azienda Ospedaliero Universitaria Di Bologna, Bologna
Policlinico S. Orsola-Ematologia LA Seragnoli, Bologna
Hospital Universitario Virgen del Rocío, Seville
Froedtert & Medical College of Wisconsin & Affiliated Hospitals, Milwaukee
University of Kansas Cancer Center, Fairway
FN Ostrava / Ostrava, Ostrava
Banner Health, Gilbert
University of California, San Diego, La Jolla
Aarhus University Hospital, Aarhus
Rigshospitalet, Copenhagen
The Finsen Centre, National Hospital, Copenhagen
Hospital Germans Trias Pujol, Barcelona
Lead Sponsor
Incyte Corporation
INDUSTRY